ReNeuron Group PLC (AIM:RENE, OTC:RNUGF), a stem cell-derived exosome-based drug delivery platform developer, is currently seeking new investors to enable the company to trade as a going concern following its exit from administration. The company’s proprietary CustomEX™ platform can be optimized for specific tissue targets and payloads, leading to improved therapeutic outcomes and reduced off-target effects.
In recent updates, ReNeuron has highlighted its focus on generating in vivo data and validating its exosome delivery technology platform. The company plans to conduct head-to-head studies with competitors to produce the necessary data for the commercial validation of the platform. This strategic move comes after the company extended its cash runway into 2024 following a restructuring undertaken in 2022.
ReNeuron’s executive chairman, Iain Ross, emphasized the company’s commitment to advancing its exosome technology. The company’s selective delivery of complex drug modalities could be highly attractive to potential partners, according to Liberum, ReNeuron’s house broker. The broker has restated a buy rating for the company, with the core investment hypothesis remaining intact.
Despite the company’s promising technology, ReNeuron faces financial challenges, discussions are ongoing with potential funders, but the completion of a proposed fundraise would be conditional on the company exiting administration while retaining sufficient funds to settle all known creditors. The new funds raised would be used for working capital requirements post-administration.
ReNeuron’s focus remains on generating in vivo data and validating its exosome delivery technology platform. The company plans to conduct head-to-head studies with competitors to produce the necessary data for the commercial validation of the platform. This strategic move comes after the company extended its cash runway into 2024 following a restructuring undertaken in 2022.
As ReNeuron navigates its financial situation, the potential for targeted delivery of complex drug modalities positions the company as an attractive partner for pharmaceutical companies seeking innovative drug delivery solutions. The company’s executive chairman, Iain Ross, emphasizes ReNeuron’s commitment to advancing its exosome technology, which could be highly attractive to potential partners, according to Liberum, ReNeuron’s house broker.
Post Disclaimer
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.